Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Michael Schopis

Gastroenterology New York, NY Medical Doctor

NPI 1386175123 CMS profile 11440508

56 W 45Th St Ste 802, New York, NY 10036

Open in the dashboard

General payments

$9,889

397 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Schopis of New York, NY is reported in the CMS Open Payments database as having received $9,889 across 397 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,828 195
2024 General $3,093 132
2023 General $1,967 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Schopis
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Michael Schopis were reported at $4,828. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Michael Schopis Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $0 $352 $106–$1,054 $132
2022 $0 $448 $129–$1,270 $149
2023 $1,967 $533 $150–$1,390 $160
2024 $3,093 $605 $160–$1,606 $164
2025 $4,828 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $3,169 159 payments
  2. AbbVie, Inc. $1,475 59 payments
  3. Janssen Biotech, Inc. $1,063 43 payments
  4. Celltrion USA Inc. $532 19 payments
  5. QOL Medical, LLC $460 11 payments
  6. Pfizer Inc. $442 22 payments
  7. Genzyme Corporation $423 3 payments
  8. Regeneron Healthcare Solutions, Inc. $390 7 payments
  9. Ardelyx, Inc. $388 17 payments
  10. RedHill Biopharma Inc. $279 12 payments
  11. Other $1,268 45 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $9,889 397 payments
Products named General payments · program years 2023–2025
  1. XIFAXAN $2,618 123 payments
  2. TREMFYA $882 37 payments
  3. RINVOQ $711 38 payments
  4. VEGZELMA $532 19 payments
  5. SKYRIZI Immunology $478 19 payments
  6. VELSIPITY $442 22 payments
  7. DUPIXENT $423 3 payments
  8. SKYRIZI Immunology $405 17 payments
  9. IBSRELA $388 17 payments
  10. Sucraid $370 8 payments
  11. Other $3,729 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

397 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record